307 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이창범-
dc.date.accessioned2017-01-09T01:23:06Z-
dc.date.available2017-01-09T01:23:06Z-
dc.date.issued2015-05-
dc.identifier.citationCLINICAL ENDOCRINOLOGY, v. 82, NO 5, Page. 670-677en_US
dc.identifier.issn0300-0664-
dc.identifier.issn1365-2265-
dc.identifier.urihttp://onlinelibrary.wiley.com/doi/10.1111/cen.12580/abstract;jsessionid=9E1CEEF327D59AD8E0EF2294E385C5E7.f01t03-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/24960-
dc.description.abstractObjectiveDyslipidaemia and central obesity are the major factors underlying the dramatic increase in metabolic syndrome (MS). We compared the effects of early combined therapy with pitavastatin and intensive lifestyle modification (LSM) on the amelioration of each component of MS with those of LSM only. Design/Participants/MeasurementsPROPIT (a PROspective comparative clinical study to evaluate the efficacy and safety of PITavastatin in patients with metabolic syndrome) was a prospective, randomized, multicenter open-label 48-week trial. We enrolled 187 patients with MS (central obesity and prediabetes) and randomized them into two treatment groups: 2mg pitavastatin daily+intensive LSM or intensive LSM only. The primary outcome was the improvements in the components of MS and in the percentage of non-MS converters. ResultsAfter 1year treatment, the improvement of MS score was significantly higher in the pitavastatin+LSM group (P=0039). However, non-MS converters (MS score 2) did not differ between the groups. The secondary outcomes, namely lipid profiles, the Apo B/A1 ratio, visceral fat/subcutaneous fat ratio and the Framingham risk score, were significantly improved in the pitavastatin group. There was no deterioration in glucose metabolism after treatment with pitavastatin for 1year. ConclusionsEarly statin treatment can be an effective option in obese patients with MS, prediabetes and mild dyslipidaemia with further improvement of cardiovascular risk factors. We could not observe the increase rate of glucose intolerance in statin group. Future longitudinal studies are needed to test the benefits of early statin treatment compared with LSM.en_US
dc.description.sponsorshipThis study was sponsored by Choong Wae pharmaceutical company (JW pharmaceutical), Korea. The sponsor company 'JW pharmaceutical' did not have any role for designing, data collection, data analysis and writing the manuscript.en_US
dc.language.isoenen_US
dc.publisherWILEY-BLACKWELLen_US
dc.subjectC-REACTIVE PROTEINen_US
dc.subjectHYPERCHOLESTEROLEMIC PATIENTSen_US
dc.subjectHYPERLIPIDEMIC PATIENTSen_US
dc.subjectDIABETES-MELLITUSen_US
dc.subjectNATIONAL-HEALTHen_US
dc.subjectADIPONECTINen_US
dc.subjectRISKen_US
dc.subjectINTERVENTIONen_US
dc.subjectSTATEMENTen_US
dc.subjectDIAGNOSISen_US
dc.titlePROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndromeen_US
dc.typeArticleen_US
dc.relation.no5-
dc.relation.volume82-
dc.identifier.doi10.1111/cen.12580-
dc.relation.page670-677-
dc.relation.journalCLINICAL ENDOCRINOLOGY-
dc.contributor.googleauthorChoi, Sung Hee-
dc.contributor.googleauthorLim, Soo-
dc.contributor.googleauthorHong, Eun Shil-
dc.contributor.googleauthorSeo, Ji A.-
dc.contributor.googleauthorPark, Cheol-Young-
dc.contributor.googleauthorNoh, Jung Hyun-
dc.contributor.googleauthorMok, Ji Oh-
dc.contributor.googleauthorLee, Ki Young-
dc.contributor.googleauthorPark, Jong Sook-
dc.contributor.googleauthorKim, Dae Jung-
dc.contributor.googleauthorLee, Chang Beom-
dc.contributor.googleauthorKim, Sung Rae-
dc.contributor.googleauthorJang, Hak Chul-
dc.relation.code2015001817-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidlekang-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE